A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
Clinical trial NCT04508023 · TERMINATED
Trial details
- NCT number
- NCT04508023
- Sponsor
- Janssen Research & Development, LLC
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-13
- Primary completion
- 2022-06-01
- Enrollment
- 1284
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.